Have a feature idea you'd love to see implemented?
Let us know!
SLDB Solid Biosciences Inc
Price (delayed)
$5.23
Market cap
$208.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.04
Enterprise value
$169.29M
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by
Highlights
The EPS rose by 33% year-on-year and by 8% since the previous quarter
The debt fell by 8% YoY and by 2.3% QoQ
The equity is up by 16% year-on-year but it has declined by 14% since the previous quarter
SLDB's quick ratio is down by 42% since the previous quarter and by 18% year-on-year
The net income fell by 13% QoQ and by 13% YoY
Key stats
What are the main financial stats of SLDB
Market
Valuations
Earnings
Shares outstanding
39.95M
Market cap
$208.96M
Enterprise value
$169.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.21
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$102.17M
EBITDA
-$98.17M
Free cash flow
-$91.73M
Per share
Balance sheet
Liquidity
EPS
-$3.04
Free cash flow per share
-$2.21
Book value per share
$4.33
Revenue per share
$0
TBVPS
$5.11
Total assets
$211.83M
Total liabilities
$44.8M
Debt
$24.72M
Equity
$167.02M
Working capital
$156.64M
Debt to equity
0.15
Current ratio
7.85
Quick ratio
7.49
Net debt/EBITDA
0.4
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-47.8%
Return on equity
-58.7%
Return on invested capital
-75.9%
Return on capital employed
-54.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLDB stock price
How has the Solid Biosciences stock price performed over time
Intraday
5.44%
1 week
-1.51%
1 month
-10.14%
1 year
117.92%
YTD
-14.82%
QTD
-24.96%
Financial performance
How have Solid Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$112.1M
Net income
-$102.44M
Gross margin
N/A
Net margin
N/A
The net income fell by 13% QoQ and by 13% YoY
The operating income has declined by 12% since the previous quarter but it has grown by 3.8% year-on-year
Growth
What is Solid Biosciences's growth rate over time
Valuation
What is Solid Biosciences stock price valuation
P/E
N/A
P/B
1.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 33% year-on-year and by 8% since the previous quarter
The price to book (P/B) is 19% less than the 5-year quarterly average of 1.5 and 19% less than the last 4 quarters average of 1.5
The equity is up by 16% year-on-year but it has declined by 14% since the previous quarter
Efficiency
How efficient is Solid Biosciences business performance
The return on assets has declined by 16% year-on-year and by 9% since the previous quarter
Solid Biosciences's return on equity has decreased by 14% YoY and by 9% QoQ
The ROIC is down by 12% QoQ but it is up by 6% YoY
Dividends
What is SLDB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLDB.
Financial health
How did Solid Biosciences financials performed over time
SLDB's quick ratio is down by 42% since the previous quarter and by 18% year-on-year
Solid Biosciences's current ratio has decreased by 42% QoQ and by 16% YoY
The debt is 85% lower than the equity
The debt to equity has contracted by 21% YoY but it has grown by 15% from the previous quarter
The equity is up by 16% year-on-year but it has declined by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.